2,5-Dimethylpiperazine, trans- → 5-[8-(trans-2,5-Dimethylpiperazin-1-yl)-9-isobutyl-6-morpholin-4-yl-9H-purin-2-yl]pyrimidin-2-amine

HRID 421356

Reaktionsgleichung

[CH3:1][C@H:2]1[CH2:7][NH:6][C@H:5]([CH3:8])[CH2:4][NH:3]1.Cl[C:10]1[N:11]([CH2:32][CH:33]([CH3:35])[CH3:34])[C:12]2[C:17]([N:18]=1)=[C:16]([N:19]1[CH2:24][CH2:23][O:22][CH2:21][CH2:20]1)[N:15]=[C:14]([C:25]1[CH:26]=[N:27][C:28]([NH2:31])=[N:29][CH:30]=1)[N:13]=2>CN1CCCC1=O>[CH3:1][C@H:2]1[CH2:7][NH:6][C@H:5]([CH3:8])[CH2:4][N:3]1[C:10]1[N:11]([CH2:32][CH:33]([CH3:35])[CH3:34])[C:12]2[C:17]([N:18]=1)=[C:16]([N:19]1[CH2:20][CH2:21][O:22][CH2:23][CH2:24]1)[N:15]=[C:14]([C:25]1[CH:26]=[N:27][C:28]([NH2:31])=[N:29][CH:30]=1)[N:13]=2

Komponenten

Reaktionsbedingungen

Temperatur: 150 °C

Versuchsvorschrift

trans-2,5-Dimethylpiperazine (150 mg, 1.3 mmol) and N-methylpyrrolidone (1 ml) were added to 5-(8-chloro-9-isobutyl-6-morpholin-4-yl-9H-purin-2-yl)pyrimidin-2-amine (100 mg, 0.26 mmol) and the resulting mixture was stirred at 150° C. for 48 hours. The reaction mixture was cooled and partitioned with methylene chloride and water, the organic layer was dried over magnesium sulfate, and the solvent was concentrated under reduced pressure. The residue was purified by preparative HPLC (column, NOMURA Develosil Combi-RP-5; mobile phase, acetonitrile/water/formic acid) to give the title compound (120 mg) as a pale yellow solid.

Aufarbeitung

temperatureThe reaction mixture was cooled
custompartitioned with methylene chloride and water
dry with materialthe organic layer was dried over magnesium sulfate
concentrationthe solvent was concentrated under reduced pressure
customThe residue was purified by preparative HPLC (column, NOMURA Develosil Combi-RP-5; mobile phase, acetonitrile/water/formic acid)

Quellen und Nachweise

ORD-Eintrag: ord-65687781f1df46848595e6d42acdc07c
Quelldatensatz: uspto-grants-2012_01
DOI: 10.6084/m9.figshare.5104873.v1
Patentnummer: US08097622B2

Verknüpfte Notizen

Wird geladen…